Beijing Konruns Pharmaceutical Co.,Ltd.
SHH: 603590.SS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Zhanqi Niu
- Employees
- 668
- Headquarters
- Beijing, China
- IPO year
- 2018
- Market cap
- CN¥5.7B
- Website
- https://www.konruns.cn
Loading 603590…
Loading profile data…Frequently asked questions about 603590
What does Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS) do?
Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research, production, and sale of various drugs in China. The company offers Su Ling product in the hemagglutinin preparation market used to reduce bleeding during surgery and control postoperative surgery. It also engages in the development of drug candidates, including CX1026, CX1003, and...
Where does 603590.SS trade?
Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS) trades on the Shanghai Stock Exchange.
What sector is 603590.SS in?
Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Beijing Konruns Pharmaceutical Co.,Ltd.?
Zhanqi Niu is the chief executive officer of Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS).
Where is Beijing Konruns Pharmaceutical Co.,Ltd. headquartered?
Beijing Konruns Pharmaceutical Co.,Ltd. is headquartered in China.
Does 603590.SS pay a dividend?
Yes — Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS) paid a trailing twelve-month dividend of CNY 0.60 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 603590.SS go public?
Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS) completed its initial public offering in 2018.